Logo image of SCANA.OL

SCANA ASA (SCANA.OL) Stock Fundamental Analysis

OSL:SCANA - Euronext Oslo - NO0003053308 - Common Stock - Currency: NOK

1.582  -0.04 (-2.35%)

Fundamental Rating

6

Taking everything into account, SCANA scores 6 out of 10 in our fundamental rating. SCANA was compared to 110 industry peers in the Machinery industry. While SCANA belongs to the best of the industry regarding profitability, there are concerns on its financial health. SCANA is evaluated to be cheap and growing strongly. This does not happen too often!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

SCANA had positive earnings in the past year.
SCANA had a positive operating cash flow in the past year.
Of the past 5 years SCANA 4 years were profitable.
In the past 5 years SCANA always reported a positive cash flow from operatings.
SCANA.OL Yearly Net Income VS EBIT VS OCF VS FCFSCANA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of SCANA (5.30%) is better than 70.00% of its industry peers.
SCANA has a Return On Equity of 12.56%. This is in the better half of the industry: SCANA outperforms 73.64% of its industry peers.
SCANA has a better Return On Invested Capital (10.69%) than 81.82% of its industry peers.
Industry RankSector Rank
ROA 5.3%
ROE 12.56%
ROIC 10.69%
ROA(3y)2.29%
ROA(5y)7.89%
ROE(3y)5.28%
ROE(5y)21.93%
ROIC(3y)N/A
ROIC(5y)N/A
SCANA.OL Yearly ROA, ROE, ROICSCANA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

With a Profit Margin value of 4.23%, SCANA perfoms like the industry average, outperforming 56.36% of the companies in the same industry.
SCANA's Profit Margin has improved in the last couple of years.
The Operating Margin of SCANA (7.49%) is better than 60.91% of its industry peers.
SCANA's Operating Margin has improved in the last couple of years.
SCANA has a better Gross Margin (53.34%) than 69.09% of its industry peers.
In the last couple of years the Gross Margin of SCANA has grown nicely.
Industry RankSector Rank
OM 7.49%
PM (TTM) 4.23%
GM 53.34%
OM growth 3Y35.21%
OM growth 5Y249.35%
PM growth 3Y-21.66%
PM growth 5Y10.48%
GM growth 3Y6.46%
GM growth 5Y7.06%
SCANA.OL Yearly Profit, Operating, Gross MarginsSCANA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), SCANA is creating some value.
The number of shares outstanding for SCANA has been increased compared to 1 year ago.
SCANA has more shares outstanding than it did 5 years ago.
SCANA has a better debt/assets ratio than last year.
SCANA.OL Yearly Shares OutstandingSCANA.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
SCANA.OL Yearly Total Debt VS Total AssetsSCANA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

The Debt to FCF ratio of SCANA is 7.37, which is on the high side as it means it would take SCANA, 7.37 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of SCANA (7.37) is comparable to the rest of the industry.
SCANA has a Debt/Equity ratio of 0.57. This is a neutral value indicating SCANA is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.57, SCANA perfoms like the industry average, outperforming 41.82% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF 7.37
Altman-Z N/A
ROIC/WACC1.33
WACC8.04%
SCANA.OL Yearly LT Debt VS Equity VS FCFSCANA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

SCANA has a Current Ratio of 1.12. This is a normal value and indicates that SCANA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of SCANA (1.12) is worse than 78.18% of its industry peers.
A Quick Ratio of 0.93 indicates that SCANA may have some problems paying its short term obligations.
The Quick ratio of SCANA (0.93) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.93
SCANA.OL Yearly Current Assets VS Current LiabilitesSCANA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

8

3. Growth

3.1 Past

SCANA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.46%.
Measured over the past years, SCANA shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.84% on average per year.
Looking at the last year, SCANA shows a very strong growth in Revenue. The Revenue has grown by 22.66%.
Measured over the past years, SCANA shows a very strong growth in Revenue. The Revenue has been growing by 40.40% on average per year.
EPS 1Y (TTM)5.46%
EPS 3Y-9.67%
EPS 5Y20.84%
EPS Q2Q%-36.17%
Revenue 1Y (TTM)22.66%
Revenue growth 3Y86.39%
Revenue growth 5Y40.4%
Sales Q2Q%8.76%

3.2 Future

Based on estimates for the next years, SCANA will show a very strong growth in Earnings Per Share. The EPS will grow by 34.80% on average per year.
The Revenue is expected to grow by 10.21% on average over the next years. This is quite good.
EPS Next Y19.33%
EPS Next 2Y39.53%
EPS Next 3Y34.8%
EPS Next 5YN/A
Revenue Next Year1.92%
Revenue Next 2Y9.54%
Revenue Next 3Y10.21%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SCANA.OL Yearly Revenue VS EstimatesSCANA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
SCANA.OL Yearly EPS VS EstimatesSCANA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 9.89, the valuation of SCANA can be described as very reasonable.
Based on the Price/Earnings ratio, SCANA is valued cheaper than 83.64% of the companies in the same industry.
SCANA is valuated cheaply when we compare the Price/Earnings ratio to 26.20, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 8.08, the valuation of SCANA can be described as very reasonable.
84.55% of the companies in the same industry are more expensive than SCANA, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of SCANA to the average of the S&P500 Index (22.13), we can say SCANA is valued rather cheaply.
Industry RankSector Rank
PE 9.89
Fwd PE 8.08
SCANA.OL Price Earnings VS Forward Price EarningsSCANA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SCANA is valued cheaply inside the industry as 81.82% of the companies are valued more expensively.
SCANA's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. SCANA is cheaper than 72.73% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.16
EV/EBITDA 4.68
SCANA.OL Per share dataSCANA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of SCANA may justify a higher PE ratio.
SCANA's earnings are expected to grow with 34.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.51
PEG (5Y)0.47
EPS Next 2Y39.53%
EPS Next 3Y34.8%

0

5. Dividend

5.1 Amount

No dividends for SCANA!.
Industry RankSector Rank
Dividend Yield N/A

SCANA ASA

OSL:SCANA (5/28/2025, 7:00:00 PM)

1.582

-0.04 (-2.35%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)N/A N/A
Inst Owners0.14%
Inst Owner ChangeN/A
Ins Owners9.84%
Ins Owner ChangeN/A
Market Cap730.71M
Analysts86.67
Price Target3.47 (119.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.05
Dividend Growth(5Y)-61.68%
DP27.13%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.65%
Min EPS beat(2)-2.91%
Max EPS beat(2)26.21%
EPS beat(4)2
Avg EPS beat(4)13.67%
Min EPS beat(4)-96.76%
Max EPS beat(4)128.16%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.45%
Min Revenue beat(2)-11.67%
Max Revenue beat(2)0.77%
Revenue beat(4)3
Avg Revenue beat(4)5.62%
Min Revenue beat(4)-11.67%
Max Revenue beat(4)23.76%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 9.89
Fwd PE 8.08
P/S 0.37
P/FCF 11.16
P/OCF 4.99
P/B 1.1
P/tB 2.61
EV/EBITDA 4.68
EPS(TTM)0.16
EY10.11%
EPS(NY)0.2
Fwd EY12.37%
FCF(TTM)0.14
FCFY8.96%
OCF(TTM)0.32
OCFY20.05%
SpS4.27
BVpS1.44
TBVpS0.61
PEG (NY)0.51
PEG (5Y)0.47
Profitability
Industry RankSector Rank
ROA 5.3%
ROE 12.56%
ROCE 14.11%
ROIC 10.69%
ROICexc 10.77%
ROICexgc 17.06%
OM 7.49%
PM (TTM) 4.23%
GM 53.34%
FCFM 3.32%
ROA(3y)2.29%
ROA(5y)7.89%
ROE(3y)5.28%
ROE(5y)21.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y8.14%
ROICexcg growth 5Y203.17%
ROICexc growth 3Y-6.18%
ROICexc growth 5Y178.96%
OM growth 3Y35.21%
OM growth 5Y249.35%
PM growth 3Y-21.66%
PM growth 5Y10.48%
GM growth 3Y6.46%
GM growth 5Y7.06%
F-Score8
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF 7.37
Debt/EBITDA 1.46
Cap/Depr 71.68%
Cap/Sales 4.11%
Interest Coverage 3.83
Cash Conversion 56.22%
Profit Quality 78.63%
Current Ratio 1.12
Quick Ratio 0.93
Altman-Z N/A
F-Score8
WACC8.04%
ROIC/WACC1.33
Cap/Depr(3y)42.24%
Cap/Depr(5y)32.52%
Cap/Sales(3y)2.78%
Cap/Sales(5y)1.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3Y-9.67%
EPS 5Y20.84%
EPS Q2Q%-36.17%
EPS Next Y19.33%
EPS Next 2Y39.53%
EPS Next 3Y34.8%
EPS Next 5YN/A
Revenue 1Y (TTM)22.66%
Revenue growth 3Y86.39%
Revenue growth 5Y40.4%
Sales Q2Q%8.76%
Revenue Next Year1.92%
Revenue Next 2Y9.54%
Revenue Next 3Y10.21%
Revenue Next 5YN/A
EBIT growth 1Y77.19%
EBIT growth 3Y152.01%
EBIT growth 5Y390.48%
EBIT Next Year82.48%
EBIT Next 3Y36.44%
EBIT Next 5YN/A
FCF growth 1Y-47.68%
FCF growth 3Y41.29%
FCF growth 5Y3.96%
OCF growth 1Y-7.22%
OCF growth 3Y80.15%
OCF growth 5Y20.9%